The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Management attributed first-quarter outperformance to disciplined expense management and the rapid scaling of AI-driven productivity tools across hospitals and back-office functions.

The USPI segment continues to shift toward higher acuity, evidenced by double-digit same-store volume growth in total joint replacements within ambulatory surgery centers.

Operational teams successfully mitigated headwinds from two major winter storms and vendor cyberattacks by rescheduling procedures and flexing cost structures in real-time.

The Hospital segment's performance was impacted by a 41% decline in respiratory admissions, which represented a 90 basis point reduction in admissions growth, though the company managed through these dynamics to deliver on its commitments.

Management emphasized a 'green light/red light' governance model for technology pilots, ensuring rapid scaling of successful AI tools like ambient scribes and autonomous coding while quickly shutting down ineffective ones.

Strategic portfolio shifts have concentrated assets in markets where Tenet can effectively execute high-acuity transfer center strategies and emergency-related service growth.

Full-year 2026 guidance remains reaffirmed as management monitors the 'transitionary period' of exchange enrollment declines and Medicaid redeterminations.

The company expects to invest approximately $250 million annually in USPI M&A, with half of that target already committed through the acquisition of 7 ASCs in the first quarter.

Guidance for the remainder of the year assumes a 20% reduction in exchange volumes, though first-quarter declines of 10% suggest potential for a more mitigated impact than initially modeled.

Capital allocation will prioritize share repurchases at current valuations, supported by significant free cash flow generation and a deleveraged balance sheet with no major maturities until 2027.

Management is focused on sustaining a 10% normalized year-over-year growth target for the Hospital segment through the execution of expense management initiatives and a focus on higher acuity service offerings.

A one-time $40 million favorable revenue adjustment was recognized in the quarter following the completion of the Conifer transaction.

Uncompensated care saw a slight increase, which management partially attributes to the expiration of exchange subsidies and potential hesitation in border communities regarding Medicaid enrollment.

Payer disputes and denials remain at levels management considers 'too high' compared to pre-pandemic benchmarks, though the net impact was stable relative to 2025.

The Hospital segment's revenue per adjusted admission was impacted by a $40 million year-over-year headwind from out-of-period supplemental Medicaid revenues reported in Q1 2025.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Outperformance is driven by a global strategy of increasing acuity and emergency services, implemented locally across all remaining markets in the transformed portfolio.

Management highlighted 'old-fashioned discipline' in flexing labor costs (SWB) relative to top-line fluctuations as a key driver of margin stability.

Exchange admissions were down 10%, which is less severe than the 20% full-year decline assumed in the guidance framework.

Management noted a 'tone of hesitation' in some border communities regarding primary care, though hospital-based acute care remains less affected by these sentiment shifts.

Improving throughput is essential to 'capital avoidance,' as it creates bed capacity for high-acuity transfers without requiring physical facility expansion.

Despite the natural headwind of longer stays for complex cases, AI tools for automated discharge summaries are helping keep LOS better than breakeven.

Tenet's scale allows it to transition single-specialty centers to multispecialty hubs and implement sophisticated 'dirty and clean' surgical protocols that improve OR efficiency.

The company remains highly selective, stating they 'say no to more centers than we say yes to' despite a robust M&A pipeline.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.